Drug intelligence / Profile preview

COMPOUND 6

Development stage: Preclinical
Lead developer: Curadev Therapeutics
Modality: Small Molecules

Overview

COMPOUND 6 is a small molecule inhibitor of Traf2- and Nck-interacting kinase (TNIK) being developed by Curadev for the treatment of liver fibrosis and metabolic disorders. TNIK is a member of the Ste20-like kinase family and a key component of the Wnt/beta-catenin signaling pathway, which plays a central role in the activation of myofibroblasts and the progression of tissue fibrosis. By inhibiting TNIK, COMPOUND 6 aims to suppress fibrotic gene expression and modulate metabolic pathways associated with liver disease. The program is currently in the preclinical stage of development.

Targets

TNIK (TRAF2- and NCK-interacting kinase)

Beyond the preview

Go deeper on COMPOUND 6.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on COMPOUND 6.

Explore the full profile